Evidence map›Paper›PMID 37175530›Full record

ArticleInternational journal of molecular sciences2023

NF-κB Signaling Modulates miR-452-5p and miR-335-5p Expression to Functionally Decrease Epithelial Ovarian Cancer Progression in Tumor-Initiating Cells.

Rahul D Kamdar, Brittney S Harrington, Emma Attar, Soumya Korrapati, Jyoti Shetty, Yongmei Zhao, Bao Tran, Nathan Wong, Carrie D House, Christina M Annunziata

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Rahul D KamdarWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Brittney S HarringtonWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-7083-069X
Emma AttarWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Soumya KorrapatiWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jyoti ShettyCCR Sequencing Facility, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
Yongmei ZhaoCCR Sequencing Facility, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.ORCID 0000-0003-0800-4658
Bao TranCCR Sequencing Facility, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.
Nathan WongAdvanced Biomedical Computational Science, Frederick National Laboratory for Cancer Research, Frederick, MD 21701, USA.ORCID 0000-0002-8882-3401
Carrie D HouseWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-1870-5872
Christina M AnnunziataWomen's Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-2033-6532
National Institutes of Health · USLeidos (United States) · US

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI PENDLETON, RICHARD · 2019 to 2025
$3932.6M
CCR Collaborative Bioinformatics ResourceZICBC011532 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MALIK, MARIAM · 2013 to 2025
$33.7M
Nuclear Factor-kappaB in Ovarian CancerZIABC011054 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI ANNUNZIATA, CHRISTINA · 2009 to 2023
$12.1M
Role of NF-kB signaling in supporting ovarian cancer tumor-initiating cells responsible for cancer recurrenceR00CA204727 · NCI · SAN DIEGO STATE UNIVERSITY · PI HOUSE, CARRIE DANIELLE · 2018 to 2020
$861k
Intramural NIH HHS ZIA BC011054NCI NIH HHS 75N91019D00024NCI NIH HHS R00 CA204727NCI NIH HHS ZIA BC011054
6 · The paper itself

Abstract

Epithelial ovarian cancer (EOC) remains the fifth leading cause of cancer-related death in women worldwide, partly due to the survival of chemoresistant, stem-like tumor-initiating cells (TICs) that promote disease relapse. We previously described a role for the NF-κB pathway in promoting TIC chemoresistance and survival through NF-κB transcription factors (TFs) RelA and RelB, which regulate genes important for the inflammatory response and those associated with cancer, including microRNAs (miRNAs). We hypothesized that NF-κB signaling differentially regulates miRNA expression through RelA and RelB to support TIC persistence. Inducible shRNA was stably expressed in OV90 cells to knockdown

Indexed as

MicroRNAsOvarian NeoplasmsCarcinoma, Ovarian EpithelialCell Line, TumorFemaleHumansNeoplasm Recurrence, LocalNF-kappa BTranscription Factor RelATranscription Factor RelBMicroRNAsMIRN335 microRNA, humanMIRN452 microRNA, humanNF-kappa BRELA protein, humanRELB protein, humanTranscription Factor RelATranscription Factor RelBepithelial ovarian cancermiR-335-5pmiR-452-5pNF-κBRELARELB

Identifiers

PMID37175530
PMCPMC10178396
OpenAlexW4367053333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.